Evidence map›Paper›PMID 30035253›Full record

ArticleJournal of Alzheimer's disease reports2017

Decreased Expression of Sulfatase 2 in the Brains of Alzheimer's Disease Patients: Implications for Regulation of Neuronal Cell Signaling.

Rosebud O Roberts, Yoo Na Kang, Chunling Hu, Catherine D Moser, Shaoqing Wang, Michael J Moore, Rondell P Graham, Jin-Ping Lai, Ronald C Petersen, Lewis R Roberts

Open access · diamondAbstract read
In one paragraph

Article in Journal of Alzheimer's disease reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Journal of computational biology : a journal of computational molecular cell biology · 2023
    Article
  8. Review
  9. Genetic Mapping of Behavioral Traits Using the Collaborative Cross Resource.International journal of molecular sciences · 2022
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 2 countries.

Rosebud O RobertsDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Yoo Na KangDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Chunling HuDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Catherine D MoserDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Shaoqing WangDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Michael J MooreDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Rondell P GrahamDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Jin-Ping LaiDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Ronald C PetersenDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Lewis R RobertsDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic in Arizona · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI PETERSEN, RONALD C · 1999 to 2018
$36.9M
PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI Nicholas F. LaRusso · 2009 to 2026
$22.2M
Regulation of the Tumor Microenvironment in Hepatocellular CarcinomaR01CA165076 · NCI · MAYO CLINIC ROCHESTER · PI FERNANDEZ-ZAPICO, MARTIN ERNESTO, ROBERTS, LEWIS R · 2012 to 2016
$2.0M
Vascular /Inflammatory Predictors of MCI Risk /ProgressiK01AG028573 · NIA · MAYO CLINIC ROCHESTER · PI ROBERTS, ROSEBUD O · 2006 to 2008
$351k
NCATS NIH HHS UL1 TR000135NCI NIH HHS N01 CA015083NCI NIH HHS P30 CA015083NCI NIH HHS R01 CA165076NIA NIH HHS K01 AG028573NIA NIH HHS P50 AG016574NIA NIH HHS U01 AG006786NIDDK NIH HHS P30 DK084567
6 · The paper itself

Abstract

backgroundThe human sulfatase 1 (SULF1) and sulfatase 2 (SULF2) genes modulate cell signaling and homeostasis in many tissues. Gene expression analyses have implicated SULF2 in disease pathogenesis, including Alzheimer's disease (AD), but changes in brain SULF2 expression have not been directly established.

objectiveTo investigate the expression of SULF1 and SULF2 in brain tissues from AD cases and cognitively normal controls.

methodsAutopsy tissue from AD cases (

resultsSULF2 expression was reduced in AD cases. Compared to cognitively normal controls, SULF2 expression in AD cases was significantly decreased in the hippocampal Cornu Ammonis (CA) (mean score of 6.5 in cases versus 8.3 in controls;

conclusionDecresed SULF2 in specific regions of the brain occurs in AD.

Indexed as

Alzheimer’s diseasecognitionheparan sulfate proteoglycanshSulf2neuropathologySULF2

Identifiers

PMID30035253
PMCPMC6052874
OpenAlexW2756722491

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.